Jane Street
RADX

Jane Street’s Radiopharm Theranostics RADX Stock Holding History

Jane Street’s Portfolio RADX Stock Details RADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,469
Closed -$75.5K – 13352
2025
Q4 		$75.5K Buy
+14,469
New +$77.1K ﹤0.01% 10331

Other funds holding RADX

SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
RP
Regal Partners Sydney, NSW, Australia $1.84B AUM 54.78% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Jane Street's RADX Position: Q1 2026 in Review

Jane Street sold out of Radiopharm Theranostics (RADX) in Q1 2026, closing a stake of 14,469 shares — an estimated $75.5K sold.

Jane Street first reported a position in RADX in Q4 2025 and held it in 1 quarter. The position peaked at $75.5K in Q4 2025. 7 funds tracked by Wall St. Rank hold RADX as of Q1 2026.

  • Jane Street reported no remaining Radiopharm Theranostics position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 14,469 Radiopharm Theranostics shares in Q1 2026, an estimated $75.5K.
  • Jane Street first reported a position in Radiopharm Theranostics in Q4 2025 and held it in 1 quarter.
  • Jane Street's Radiopharm Theranostics position peaked at $75.5K in Q4 2025.
  • 7 funds tracked by Wall St. Rank held Radiopharm Theranostics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.